Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancer
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000003703
- Lead Sponsor
- Toho University school of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Not provided
1. Multiple malignancies 2. Serious complications(intestinal paralysis and intestinal obstruction, interstitial pneumonia, pulmonary fibrosis,renal failure, cardiac failure , liver failure) 3.Infection 4.Diarrhea 5. mechanical bowel obstruction 6.Uncontrolable pleural effusion or ascites requiring 7.History of serious drug hypersensitivity 8.Need to treatment with flucytosine, atazanavir sulfate 9.Fresh bleeding of digestive organs 10.Cirrhosis, Icterus 11.Evidence of psychiatric disability interfering with enrollment to clinical trial 12.Need to treatment with heart failure, ischemic heart disease or arrhythmia 13.Uncontrolable diabetes 14.Symptomatic brain metastasis 15.Pregnant or lactating women or women of childbearing potential. 16.Patients judged inappropriate for this study by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method